CONTACT US
Press

egnite Launches CardioCare Research Suite to Accelerate Patient Identification for Leading Cardiovascular Clinical Trials

New Capabilities Automatically Identify Patients for 10 High-Impact 
Structural Heart and Heart Failure Clinical Trials

ALISO VIEJO, Calif. – July 1, 2025 – egnite, Inc., a leading cardiovascular digital health company announced the launch of the CardioCare Research Suite, a significant expansion of its flagship platform designed to streamline and enhance patient identification for clinical trials.

The Research Suite supports ten landmark clinical trials in structural heart and heart failure care, including AIM-HIGHer, ALT-FLOW II, APOLLO, ARTIST, CLASP IIF, CLASP II TR, CORCINCH-HF, EMPOWER, ENCIRCLE, PROGRESS.

This expansion addresses a long-standing challenge in clinical research, ensuring the right patients are surfaced at the right time for trial consideration. Through the use of AI and natural language processing to analyze both structured and unstructured hospital data, the CardioCare Research Suite empowers hospitals to expand access to novel therapies and reduce the operational burden on research teams.

Early adopters of the Research Suite have reported meaningful results:

  • Over 50% of patients identified through the platform had never been seen by the principal investigator or a relevant specialist.
  • 25%–50% of patient consents were sourced directly from CardioCare.
  • Trial coordinators report significantly less time spent identifying candidates.
  • The platform facilitates more precise, patient-focused outreach by trial investigators, addressing the complexity of evolving eligibility criteria.
 

“Since our inception, ambitious programs have expressed a desire to leverage the CardioCare platform to move from passive intake to proactive identification of clinical trial patients,” said Kahla Verhoef, Chief Operating Officer at egnite. “The Research Suite is a direct response to that need, empowering research teams to efficiently surface eligible patients from complex data, align with evolving trial criteria, and engage physicians with precision and confidence.”

egnite’s CardioCare Research Suite is now an available offering to all partner hospitals using the CardioCare platform. With the ability to leverage AI across structured and unstructured data, the platform uniquely equips research teams to accelerate enrollment and drive clinical innovation forward.

__

About egnite, Inc.

egnite is a data-driven digital health company committed to advancing the health of our society through innovative cardiovascular solutions. egnite utilizes AI algorithms and big data to generate business intelligence for healthcare, elevating the role of data in critical decisions. The company, based in Aliso Viejo, California, partners with leading hospitals and life sciences organizations to transform care delivery for cardiovascular patients. For more information, visit www.egnitehealth.com.

# # #

egnite, egnite, Inc., CardioCare and the spark logo are trademarks of egnite, Inc. All other trademarks are the property of their respective owners.

Media Contact

Andro Yuson

804-998-3066

andro.yuson@egnitehealth.com

Linkedin Twitter Youtube

Related Articles
Press

egnite’s Call for Science Study on M-TEER Device Durability and Long-Term Patient Outcomes to be Featured at TCT 2026

The egnite Registry contributed de-identified, longitudinal data, linking serial echocardiograms with clinical outcomes, to help answer what happens to patients after a successful mitral transcatheter edge-to-edge repair (M-TEER) procedure.  ALISO VIEJO, Calif. — October 13, 2026 — egnite, Inc., a cardiovascular intelligence company that helps clinicians identify and manage patients with untreated heart disease, today announced that Dr. John T. Saxon, Director of the Advanced Cardiac Valve Center at University of Virginia
Publications

Mitral Regurgitation and Severe Aortic Stenosis: Clinical Characteristics, Prognostic Impact, and Response to TAVR: Insights From egnite Data

BACKGROUND Aortic stenosis (AS) and mitral regurgitation (MR) frequently co-occur, complicating diagnosis and treatment. We examined current US treatment trends and patient outcomes among patients with severe AS and at least moderate MR. METHODS We analyzed data from 2 992 362 patients (aged ≥18 years) undergoing 5 245 904 echocardiograms at 43 US institutions

"The future of aortic stenosis care requires proactive identification, longitudinal monitoring, and intentional pipeline management."
egnite Research

Rethinking the Aortic Stenosis Pipeline

Aortic stenosis care is shifting from a reactive to a proactive model. Emerging clinical evidence supports earlier identification, closer monitoring, and intentional patient management across the disease continuum. As treatment thresholds evolve, health systems need scalable approaches to identify at-risk patients, close treatment gaps, and ensure timely access to specialist care.